Adam Dahlberg
Chairman since 1999
Swedish technology investor within new materials, life science, medtech and software.
Holding in the company: 3 315 839 shares private and through companies
Independent in relation to major shareholders: No
Independent in relation to the company and management: Yes
Education: Master Economics from the Stockholm School of Economics
Other assignments: Chariman of the Board Corlina Biomedical, Member of Board of Directors Senzime AB (listed at Nasdaq)